Royal Marsden Nhs Foundation Trust

This early-stage trial aimed to test the safety of combining the immunotherapy drug pembrolizumab with targeted radiation (SBRT) in people with advanced non-small-cell lung cancer that had worsened after standard treatments. Only 2 out of a planned 24 patients were enrolled befor…

This study tested whether adding radiotherapy to the immunotherapy drug pembrolizumab could better control advanced melanoma than pembrolizumab alone. It involved 17 adults with stage III or IV melanoma that had spread. The trial was terminated early, so results are limited.

This early-phase study aimed to see if adding the immunotherapy drug pembrolizumab to standard chemoradiation is safe for people with locally advanced cervix cancer. Only 1 person enrolled before the study was stopped. The goal was to find the safest dose and check for side effec…

This early-stage trial tested whether combining the immunotherapy drug pembrolizumab with precise, high-dose radiation (SBRT) could help people with advanced malignant pleural mesothelioma, a rare cancer of the lung lining. The study aimed to check safety and side effects in pati…